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Hereditary sensory neuropathy type I (HSN I) is an axonal form of autosomal-dominant hereditary motor and sensory neuropathy
distinguished by prominent sensory loss that leads to painless injuries. Unrecognized, these can result in delayed wound healing and
osteomyelitis, necessitating distal amputations. To elucidate the genetic basis of an HSN I subtype in a family in which mutations in
the few known HSN I genes had been excluded, we employed massive parallel exon sequencing of the 14.3 Mb disease interval on chro-
mosome 14q. We detected a missense mutation (c.1065C>A, p.Asn355Lys) in atlastin-1 (ATL1), a gene that is known to be mutated in
early-onset hereditary spastic paraplegia SPG3A and that encodes the large dynamin-related GTPase atlastin-1. The mutant protein
exhibited reduced GTPase activity and prominently disrupted ER network morphology when expressed in COS7 cells, strongly support-
ing pathogenicity. An expanded screen in 115 additional HSN I patients identified two further dominant ATL1 mutations (c.196G>C
[p.Glu66Gln] and c.976 delG [p.Val326TrpfsX8]). This study highlights an unexpected major role for atlastin-1 in the function of
sensory neurons and identifies HSN I and SPG3A as allelic disorders.Recent technological developments in massive parallel
sequencing have greatly facilitated the rapid and econom-
ical detection of the molecular basis for rare Mendelian
disorders.1–3 To identify the genetic mutations responsible
for distinct forms of inherited neuromuscular disorders in
three families, we designed a 385k NimbleGen Sequence
Capture array to selectively enrich and sequence the
combined exonic information of disease-linked chromo-
somal loci. The first large family analyzed was diagnosed
clinically with hereditary sensory neuropathy type I
(HSN I [MIM 162400]), an axonal form of hereditary motor
and sensory neuropathy distinguished by prominent early
sensory loss and later positive sensory phenomena,
including dysesthesia and shooting pains. In HSN I loss
of sensation can lead to painless injuries, slow wound
healing, and subsequent osteomyelitis, requiring distal
amputations. Distal motor involvement is usually present
in advanced cases and can be severe.4 The inheritance
pattern in HSN I is autosomal dominant as a result of muta-
tions in genes encoding serine palmitoyltransferases 1 and
2 (SPTLC1 [MIM 605712] and SPTLC2 [MIM 605713])5,6
and Ras-related GTPase 7 (RAB7 [MIM 602298]).7
The anonymized pedigree of the HSN I family studied
here is shown in Figure 1. Affected and unaffected family
members underwent a detailed clinical, neurological, and
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Age at onset was in early adulthood, when most affected
individuals exhibited trophic skin and nail changes and
suffered from repeated foot ulcerations, leading to osteo-
myelitis and subsequent foot or toe amputations (Figure 2).
Most patients presented with severe distal sensory loss and
distal amyotrophy in the lower limbs but absent or
minimal distal amyotrophy in the upper limbs. Patellar
tendon reflexes ranged from normal to increased, and
ankle reflexes ranged broadly from absent to increased,
indicating upper motor-neuron involvement in some
patients. A sensorimotor axonal neuropathy was almost
consistently observed on electrophysiological testing.
One 23-year-old patient (IV/2) with electrophysiologically
prominent axonal nerve damage, but without foot ulcera-
tions, was diagnosed with cerebral palsy in infancy because
of pronounced early-onset lower-limb spasticity, but
a detailed history revealed no indications of prenatal or
perinatal hypoxia.
After mutations in the genes known to be mutated in
HSN I (SPTLC1, SPTLC2, and RAB7)5–7 were excluded,
a genome-wide linkage scan performed with Affymetrix
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Figure 1. Partial Pedigree of a Family Affected by HSN I
The pedigree shows all individuals included in the linkage study (disease status at time of diagnosis is indicated). Additional unaffected
familymembers and individuals not available for this study are not depicted for privacy. Individual II/3 was neurologically normal at the
age of 69, but NCS could not be carried out. Also, the children of this individual did not have a history of gait disturbances or foot ulcer-
ations. Medical history indicated that individuals II/9 and III/11 were unaffected, but they refused neurological and neurophysiological
examination. However, individual III/11 agreed to participate in the genetic analysis. Filled symbols indicate affected individuals; empty
symbols define unaffected individuals. U indicates patients with severe sensory neuropathy and foot ulcerations and/or amputations;
patients with a þ also presented with upper-motor-neuron signs. Neg indicates that an individual tested negative for the p.Asn355Lys
mutation.(Affymetrix, Santa Clara, CA, USA) in ten affected and five
unaffected individuals and three spouses from the HSN I
family. Calculations of the parametric multipoint LOD
score and haplotypes were obtained with the ALLEGRO
program8 and an autosomal-dominant, fully penetrant100 The American Journal of Human Genetics 88, 99–105, January 7,model. A first evaluation exclusively considering individ-
uals with foot ulcerations and/or axonal neuropathy to
be affected localized the possible disease interval to either
chromosome 5q or 14q (data not shown). However,
when the two affected individuals—individual III/3, withFigure 2. Clinical Findings in Patients
Carrying the Asn355Lys Atlastin-1 Variant
Images of the feet of patients (III/2-U, III/8-
U, and III/9-U) with prominent axonal
sensory neuropathy, trophic skin and nail
changes, distal muscle atrophy, mild pes
cavus, and amputation of the great toe
are shown.
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Figure 3. Detection of ATL1 Mutations
by Direct Sequencing
Representative electropherograms derived
from ATL1 sequencing of genomic DNA
from patients (upper panel) compared to
unaffected individuals (wild-type, lower
panel). The positions of the heterozygous
mutations are indicated with an arrow
above the sequence. Effects of the muta-
tions on amino acid sequence are shown
on the right.marked nail changes and normal nerve conduction studies
(NCS) but neuropathic changes on electromyography and
pathologically brisk tendon reflexes, and individual IV/1,
with mild spasticity but normal NCS—were included as
well, the disease interval could be linked to a single locus
on chromosome 14, bp 41,334,596–55,611,787
(Figure S1), with a maximum LOD score of 2.94. According
to the ENSEMBL database (release 54 from May 2009,
Homo sapiens Genes NCBI36), this interval contains 75
protein-encoding genes (Table S1) encompassing 924
exons.
To simultaneously analyze all 75 protein-coding genes
within the disease region, we used array-based sequence
capture followed by massive parallel resequencing. A
Roche NimbleGen custom tiling 385K sequence capture
array targeting the exonic sequences of all protein-encod-
ing genes within the disease interval was designed with Bi-
oMart EnsEMBL release 54 May 2009 on the basis of theThe American Journal of HumanNCBI 36 assembly of the human
genome (November 2005). Sequence
capture was performed according to
the manufactor’s instructions (Roche
NimbleGen). Twenty micrograms of
genomic DNA from patient II/6-U
was processed into a capture library
compatible with GS FLX Titanium
chemistry according to the Nimble-
Gen Arrays User’s Guide v.3.0, Dec.
2008 (Roche NimbleGen, Madison,
WI). Four micrograms of the ampli-
fied capture library was processed
into a sequencing library for the 454
GS-FLX according to the GS FLX Tita-
nium General Library Preparation
protocol (454 Life Sciences, Branford,
CT) according to the manufacturer’s
recommended conditions (without
the nebulization step). The captured
sample library was sequenced with
a quarter of a Titanium PicoTiterplate
(70 3 75) on the GS-FLX platform
with Titanium chemistry and stan-
dard settings. We generated
~72.11Mb of sequence information
(total of 222,522 reads), and 72.9%of uniquely mapped reads hit the target region. An effec-
tive >10-fold sequence coverage for ~76% of the target
sequence at the per base level (Figure S2) was achieved for
the HSN I subtype locus on chromosome 14.
Applying high-confidence sequence-variant filtering
with the standard GS Reference Mapper tool (reference:
UCSC genome annotation database for the Mar. 2006
GenBank freeze assembled by NCBI hg18 build 36.1,
dbSNP build 130) and manual curation, we identified
27 nonsynonymous sequence variants (Table S2), 25 of
which were known single-nucleotide polymorphisms
(dbSNPs). The two remaining sequence variants, both
confirmed by Sanger sequencing, were not previously
reported. Both segregated with the disease and affected
the coding sequences of atlastin-1 (ATL1, NM_015915.4,
c.1065C>A [p.Asn355Lys]; MIM 606439; Figure 3) and
prostaglandin E receptor 2 (PTGER2, NM_000956.3,
c.247T>G [p.Cys83Gly]; MIM 176804). Whereas detectionGenetics 88, 99–105, January 7, 2011 101
of the PTGER2 sequence variant in 1/40 healthy control
individuals points to a probable polymorphism, the
missense variation p.Asn355Lys ATL1 at a highly
conserved residue (Figure S3) was absent in 370 ethnically
and age-matched control individuals, making disease
causality highly likely.
To evaluate further mutations in ATL1 as a potential
cause of HSN I, we tested the entire ATL1 coding region
in 115 additional patients classified as having familial or
sporadic HSN I (for primer sequences, see Table S3); addi-
tional ATL1 mutations were found in two HSN patients
for whommutations in genes with known HSN mutations
had been excluded previously (these genes include
SPTLC1, SPTLC2, RAB7, WNK1 [MIM 605232], NTRK
[MIM 191315], NGFB [MIM 162030], FAM134B [MIM
613114], CCT5 [MIM 610150], and the candidate genes
SPTLC3 [MIM 611120], and NGFR [MIM 162010]). Patient
A, aged 61 years, carried the missense change c.196G>C
(p.Glu66Gln, Figure 3) at a highly conserved residue coded
by exon 2 (Figure S3). He presented with progressive,
ascending, severe sensory loss affecting all modalities in
the lower legs but without foot ulcerations or paresis.
Patellar tendon reflexes were reduced, and Achilles tendon
reflexes were absent. Sural nerve biopsy revealed severe,
chronic, slowly progressive neuropathy predominantly of
the axonal type, and a moderate demyelinating compo-
nent and minimal signs of regeneration were present.
By report, the deceasedmother had a similar severe sensory
neuropathy of unknown etiology, but DNA was not
available for genetic testing. Exon 9 of patient B
contained a c.976delG nucleotide deletion predicted to
cause a large C-terminal protein truncation of atlastin-1
(p.Val326TrpfsX8, Figure 3). This patient had adult-onset
sensory neuropathy with ulcerations and lack of pain
perception. There was neither muscle weakness nor auto-
nomic symptoms. The patient had paresthesias in the
fingers and occasional lancinating pains in his ankles.
Patellar tendon reflexes were brisk, and Achilles tendon
reflexes were absent. Electrophysiological testing was
consistent with a sensorimotor axonal neuropathy. The
father of patient B displayed a similar clinical phenotype
and also carried this nucleotide deletion. According to
his medical history, the index patient has one affected
brother and two unaffected siblings; none of these individ-
uals were available for testing or examination.
Subsequently, we investigated the functional conse-
quences of these ATL1 mutations. COS7 cells were main-
tained, transfected with eukaryotic expression constructs,
and analyzed by confocal immunofluorescence micros-
copy and immunoblotting as described previously.9–11
Site-directed mutagenesis was performed via the Quik-
Change method (Stratagene, La Jolla, CA). GTPase activity
assays were performed with wild-type or mutant Myc-
tagged atlastin-1 proteins immunopurified from COS7
cell extracts as described previously.12 In GTPase assays,
the HSN I-associated Asn355Lys atlastin-1 mutant had
partial but significant loss of GTPase activity in vitro102 The American Journal of Human Genetics 88, 99–105, January 7,when it was compared to wild-type atlastin-1 (Figure 4A).
Expression of wild-type atlastin-1 in COS7 cells results in
amore highly branched ER and punctate enrichment of at-
lastin-1 along the ER tubules, including at three-way junc-
tions in the cell periphery and within aberrant ER sheets
more centrally.11,13 Expression of Asn355Lys atlastin-1 in
COS7 cells, at levels essentially identical to those of the
wild-type protein, yielded prominent disruption of ER
three-way junctions, similar to results seen upon expres-
sion of the Lys80Ala dominant-negative atlastin-1 mutant
(equivalent to Lys44Ala in the dynamin GTPase) that lacks
GTPase activity (Figures 4B–4D). However, the Glu66Gln
atlastin-1 mutant exhibited no significant changes in
GTPase activity compared to that of the wild-type protein.
Also, no changes in ER morphology in COS7 cells were
observed for the Glu66Gln atlastin-1 mutant when it was
expressed at levels similar to those of the wild-type protein
(Figure S4). Finally, the Val326TrpfsX8 atlastin-1 trunca-
tion mutant was localized diffusely throughout the cyto-
plasm in COS7 cells as a result of the lack of the C-terminal
paired transmembrane domains11 that are necessary and
sufficient for ER localization, but it did not significantly
alter ER morphology, as assessed by coexpression with
wild-type atlastin-1 and also by coexpression with RFP-
tagged Sec61b, a resident ER protein (Figure S4). Impor-
tantly, immunoblot analysis (Figure S4) showed that
expression levels of Val326TrpfsX8 atlastin-1 were mark-
edly lower than those of wild-type atlastin-1 or the
Glu66Gln and Asn355Lys mutants, probably as a result
of decreased protein stability. These data indicate that
disease pathogenesis, particularly in the case of
Val326TrpfsX8 atlastin-1, might be related to loss of func-
tional atlastin-1 protein, which has been shown to alter ER
morphology.13,14 Even so, the absence of any clear patho-
genic changes in heterologous cell expression studies,
particularly for Glu66Gln atlastin-1, indicate that alter-
ations in three-way junction formation of the tubular ER
might not be a sensitive indicator for all types of atlastin-
1 dysfunction. Consistent with this notion, a number of
SPG3A mutant atlastin-1 proteins do not noticeably affect
formation of three-way ER junctions, and this morpholog-
ical change appears to correlate most closely with a given
mutation’s effects on atlastin-1 GTPase activity (P.-P.Z.
and C.B, unpublished data). Furthermore, a number of
SPG3A mutations have been demonstrated to disrupt
other aspects of ER structure.15 Although we cannot
completely rule out the possibility that the Glu66Gln
and Val326TrpfsX8 atlastin-1 mutations are unrelated to
HSN I pathogenesis, this appears to be unlikely given the
positive family history for both patients A and B and the
fact that these mutations were undetected in the large
number of control subjects (150 for the Glu66Gln and
334 for the Val326TrpfsX8 mutation).
Mutations in ATL1, a dynamin-related GTPase with or-
thologs in all eukaryotes,13 have been described previ-
ously for early-onset hereditary spastic paraplegia
(SPG3A; MIM 182600), an inherited neurological2011
Figure 4. Asn355Lys Atlastin-1 Exhibits Altered GTPase Activity and Disrupts ER Morphology when It Is Expressed in Cells
(A) Myc-tagged wild-type atlastin-1 or the indicated missense mutants were immunopurified from COS7 cells, and GTP hydrolysis was
plotted as a function of time (top). Representative thin-layer chromatography plates show conversion of GTP toGDP (bottom). Error bars
represent means5 standard deviation.
(B) COS7 cells were transfected withMyc-tagged wild-type or mutant atlastin-1 and immunostained for Myc-epitope (red) and b-tubulin
(green). Merged images are at the right. DAPI nuclear staining is in blue. The scale bar represents 20 mm.
(C) Quantification of ER disruption (three trials of n ¼ 100 cells per condition, means5 SD); *p < 0.01.
(D) COS7 cells transfected with Myc-tagged wild-type or Asn355Lys atlastin-1 were immunoblotted for Myc-epitope. Actin levels were
monitored as a control for protein loading.disorder that affects axons of upper motor neurons in
a length-dependent manner.16 Thus far, more than 40
sequence alterations in exons 4–10, 12, and 13 of
ATL1, the vast majority missense changes (Figure 5),
have been reported for SPG3A.16–18 In a small number
of SPG3A patients, lower motor-neuron signs (e.g., distal
amyotrophy of the lower limbs), abnormal motor and
sensory NCS, and neuropathic findings on muscle and
sural nerve biopsy indicative of a complicated ATL1-
SPG3A phenotype have been noted.17 A recent study
also described additional symptoms, including seizures,
ataxia, and MRI hypertensities in some patients
harboring ATL1 mutations.18 However, the prominent
sensory disturbances and their complications produced
by the ATL1 mutations reported here are highly unex-
pected and may shed additional light on the physiolog-
ical role of atlastin-1. Structurally, most HSP-specific
mutations in SPG3A are predicted to alter amino acids
located on the surface of the globular, N-terminal region
that contains the conserved GTPase domain (amino acidThe Ameresidues 30–337), but a majority do not disrupt GTPase
motifs per se.11 Thus, these mutations might exert a path-
ogenic effect either by introducing an aberrant secondary
structure that disturbs intramolecular associations or
multimerization of atlastin-1 or by altering interactions
of atlastin-1 with other proteins. Thus far, no clear func-
tional distinction is evident between mutations causing
SPG3A and those implicated in HSN I. High-resolution
structural analysis of atlastin-1 might provide additional
insights.
Atlastin-1 interacts with spastin (i.e., SPASTor SPG4) and
the receptor expression enhancing protein-1 (REEP1, also
known as SPG31), which together are mutated in about
50% of autosomal-dominant HSP cases,18,19 through pre-
dicted intramembrane hydrophobic hairpin domains.11
These proteins function in the generation of the tubular
ER network in eukaryotes. This has led to the hypothesis
that the most common HSPs are caused by ER network
disruption, particularly via dysfunctional interactions
with the microtubule cytoskeleton.11rican Journal of Human Genetics 88, 99–105, January 7, 2011 103
Figure 5. Schematic Model of Atlastin-1 Mutations in SPG3A and HSN I
Themodel shows the distribution of autosomal-dominant, SPG3A-associated mutations and their amino acid residue changes, as well as
the novel ATL1mutations (bold letters) associated with HSN I identified in this study. Mutations known to be associated with peripheral
neuropathies are underlined. Exons 1–14 are indicated.How abnormal morphology of the ER might predispose
to a long axonopathy remains unclear. The long axons of
the corticospinal neurons, which are among the longest
axons in the body,might be severely affected by the disrup-
tion of the cooperative regulation of polarized membrane
and protein trafficking along microtubules.19 In cultured
cortical neurons, atlastin-1 is enriched in axon growth
cones, and shRNA-mediated depletion of atlastin-1
impaired axon elongation in neurons.9,11,14 Interestingly,
a very recent studyof atl1 in zebrafishdemonstrated that at-
lastin-1 knock down results in abnormal architecture of
spinal motor neurons, as well as an associated upregulation
of the bone morphogenetic protein (BMP) signaling
pathway.20 Because dysregulation of this pathway has
been implicated in a number of other forms of HSPs, it
will be important to study the interplay between regulation
of ER morphology and BMP signaling in neurons.
When comparing the HSN I clinical phenotypes caused
bymutations inSPTLC1,SPTLC2,RAB7, andATL1, apersua-
sive overlap between HSN I caused by RAB7 mutations
and that caused by ATL1 mutations is evident.7,21
In particular, the profound distal sensory loss affecting all
sensory modalities to a similar degree from disease onset
must be highlighted in both diseases. Also, in patients
with RAB7mutations, brisk tendon reflexes are common.21
Notably, both RAB7 and atlastin-1 are implicated in intra-
cellular membrane trafficking and distribution, and RAB7
interacts with the SPG21 protein maspardin.22,23 Func-
tional studies are needed for an investigation of any direct104 The American Journal of Human Genetics 88, 99–105, January 7,or indirect interactions between ATL1 and RAB7 and other
HSN I genes. Furthermore, the variable occurence of upper
and lowermotor neuron signs and trophic complications in
affected individuals could indicate the existenceofmodifier
genes and/or compensatory molecular mechanisms.
Uncovering these will lead to a better understanding of
the diverse phenotypes elicited by ATL1mutations.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article at http://www.cell.com/AJHG/.Acknowledgments
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